Research programme: cancer therapeutics - Casma Therapeutics
Alternative Names: Oncology Program 1; Oncology Program 2Latest Information Update: 03 Mar 2023
At a glance
- Originator Casma Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Autophagy stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer